In the latest trading session, Merck (MRK) closed at $80.93, marking a -1.77% move from the previous day.
Merck eyes growth beyond Keytruda with PAH drug Winrevair, aiming to offset the looming loss of exclusivity in 2028.
Dividend Yield Theory identifies Merck & Co., Inc. as undervalued, with a 4.09% yield well above its historical mean, suggesting strong total return potential. Despite Keytruda's looming patent expiration and political headwinds, Merck's robust pipeline and adaptability offer a credible path to future growth. DYT analysis projects a 42%-83% total return over four years, with Merck meeting or exceeding most fundamental quality metrics.
![]() MRK 3 months ago Paid | Quarterly | $0.81 Per Share |
![]() MRK 6 months ago Paid | Quarterly | $0.81 Per Share |
![]() MRK 9 months ago Paid | Quarterly | $0.77 Per Share |
![]() MRK 17 Jun 2024 Paid | Quarterly | $0.77 Per Share |
![]() MRK 14 Mar 2024 Paid | Quarterly | $0.77 Per Share |
29 Jul 2025 (In 3 weeks) Date | | 2.06 Cons. EPS | - EPS |
24 Apr 2025 Date | | - Cons. EPS | - EPS |
4 Feb 2025 Date | | 1.67 Cons. EPS | 1.72 EPS |
31 Oct 2024 Date | | 1.5 Cons. EPS | 1.57 EPS |
30 Jul 2024 Date | | 2.15 Cons. EPS | 2.28 EPS |
![]() MRK 3 months ago Paid | Quarterly | $0.81 Per Share |
![]() MRK 6 months ago Paid | Quarterly | $0.81 Per Share |
![]() MRK 9 months ago Paid | Quarterly | $0.77 Per Share |
![]() MRK 17 Jun 2024 Paid | Quarterly | $0.77 Per Share |
![]() MRK 14 Mar 2024 Paid | Quarterly | $0.77 Per Share |
29 Jul 2025 (In 3 weeks) Date | | 2.06 Cons. EPS | - EPS |
24 Apr 2025 Date | | - Cons. EPS | - EPS |
4 Feb 2025 Date | | 1.67 Cons. EPS | 1.72 EPS |
31 Oct 2024 Date | | 1.5 Cons. EPS | 1.57 EPS |
30 Jul 2024 Date | | 2.15 Cons. EPS | 2.28 EPS |
Drug Manufacturers - General Industry | Healthcare Sector | Robert M. Davis CEO | XMIL Exchange | US58933Y1055 ISIN |
US Country | 73,000 Employees | - Last Dividend | 3 Jun 2021 Last Split | 13 Jan 1978 IPO Date |
Merck & Co., Inc. is a global healthcare leader focused on innovating new solutions to tackle some of the most serious health challenges. Founded in 1891 and headquartered in Rahway, New Jersey, the company operates worldwide, engaging in the discovery, development, manufacturing, and marketing of pharmaceuticals and animal health products. It operates two main segments: Pharmaceutical and Animal Health. The Pharmaceutical segment is dedicated to developing and offering human health pharmaceutical products across a range of areas including oncology, cardiovascular, and diabetes, among others. The Animal Health segment works on veterinary pharmaceuticals, vaccines, and health management solutions and services. Merck serves a diverse clientele, including drug wholesalers, retailers, hospitals, government agencies, physicians, veterinarians, and pet owners. Notably, the company invests in several strategic collaborations and agreements with other pharmaceutical giants like AstraZeneca PLC and Bayer AG, aiming to enhance its product offerings and harness innovative treatments for multiple diseases.
The products and services offered by Merck & Co., Inc. span a broad spectrum of medical needs in both human and animal health sectors:
In the arena of collaborative efforts, Merck has entered into multiple significant agreements to bolster its product pipeline: